» » Research: Pertuzumab Adds 16 Months Survival Benefit to Trastuzumab and Chemo Treatment for HER2-Positive Breast Cancer

Research: Pertuzumab Adds 16 Months Survival Benefit to Trastuzumab and Chemo Treatment for HER2-Positive Breast Cancer

Updated results from the CLEOPATRA study reveal that a combination of pertuzumab, trastuzumab and chemotherapy confers a survival benefit of 16 months for patients with HER2-positive breast cancer that has spread to other parts of their body. CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive ...

Read More
You have just read an article categorized health titled Research: Pertuzumab Adds 16 Months Survival Benefit to Trastuzumab and Chemo Treatment for HER2-Positive Breast Cancer.
Written by: editor - Saturday, October 4, 2014

There are currently no comments for "Research: Pertuzumab Adds 16 Months Survival Benefit to Trastuzumab and Chemo Treatment for HER2-Positive Breast Cancer"

Post a Comment

Subscribe to: Post Comments (Atom)